We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Masimo (MASI) Announces Favorable Study Results on SpHb
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) recently announced the findings of a favorable study, wherein researchers assessed the impact of non-invasive and continuous hemoglobin monitoring with Masimo SpHb on perioperative transfusion management and postoperative patient outcomes on pediatric patients undergoing fronto-orbital advancement surgery. The results of the retrospective study were published in the Journal of Clinical Monitoring and Computing.
Notably, Masimo’s SpHb technology currently supports clinicians and patient care in above 75 countries.
The latest positive study outcome is a major stepping stone for Masimo’s non-invasive continuous hemoglobin monitoring business across the world. This is likely to solidify Masimo’s position in the global real-time patient monitoring space.
Significance of the Study
Researchers sought to investigate whether patient blood management (“PBM”), which includes non-invasive and continuous hemoglobin monitoring, might boost transfusion management and outcomes for children undergoing frontal advancement surgery. This followed their action of noting the frequency of significant hemorrhage during craniofacial reconstruction surgery and the importance of an adequate PBM policy during such surgery.
The study demonstrated that SpHb measurement in pediatric craniofacial surgery for craniosynostosis is a safe and non-invasive method to monitor hemoglobin values and help transfusion decision-making, subject to bias and inaccuracies of the device. Researchers concluded that pediatric patients who were monitored with SpHb had lower intraoperative packed red blood cell transfusion, less post-operative bleeding and shorter ICU stays.
Industry Prospects
Per a report by MarketsandMarkets, the global PBM market is projected to reach $15.3 billion by 2024 from $10.7 billion in 2019 at a CAGR of 7.4%. Factors like the rising prevalence of blood disorders, the growing number of blood donations increasing the risk of transfusion-transmitted infections, and escalation in road accidents, injuries, surgeries and trauma are expected to drive the market.
Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s business globally.
Notable Developments
This month, Masimo announced a major expansion of its leading hospital remote patient-monitoring and clinician notification platform — Masimo Patient SafetyNet. The expansion includes the addition of secure telehealth capabilities, thereby making the solution more adaptable and comprehensive.
Last month, Masimo received the FDA’s clearance for SedLine brain function monitoring for pediatric patients (one to 17 years of age) and the SedLine Pediatric EEG (electroencephalogram) Sensor. The latest clearance expands access to SedLine for all patients above the age of one in the United States.
Also, in February, Masimo announced robust fourth-quarter 2021 results, wherein it registered a solid uptick in the top line. The company also recorded a strong rebound in sensor sales (on the back of solid demand for set sensors) and robust order shipments.
Price Performance
Shares of Masimo have lost 32% in the past year compared with the industry’s 1.4% fall. The S&P 500 has risen 14.9% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 38.5% against the industry’s 53.5% fall over the past year.
Allscripts, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 16.3%. MDRX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 64.8%.
Allscripts has gained 44.2% against the industry’s 47.3% fall over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently flaunts a Zacks Rank #1.
Henry Schein has gained 25.9% compared with the industry’s 7.6% rise over the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Masimo (MASI) Announces Favorable Study Results on SpHb
Masimo Corporation (MASI - Free Report) recently announced the findings of a favorable study, wherein researchers assessed the impact of non-invasive and continuous hemoglobin monitoring with Masimo SpHb on perioperative transfusion management and postoperative patient outcomes on pediatric patients undergoing fronto-orbital advancement surgery. The results of the retrospective study were published in the Journal of Clinical Monitoring and Computing.
Notably, Masimo’s SpHb technology currently supports clinicians and patient care in above 75 countries.
The latest positive study outcome is a major stepping stone for Masimo’s non-invasive continuous hemoglobin monitoring business across the world. This is likely to solidify Masimo’s position in the global real-time patient monitoring space.
Significance of the Study
Researchers sought to investigate whether patient blood management (“PBM”), which includes non-invasive and continuous hemoglobin monitoring, might boost transfusion management and outcomes for children undergoing frontal advancement surgery. This followed their action of noting the frequency of significant hemorrhage during craniofacial reconstruction surgery and the importance of an adequate PBM policy during such surgery.
The study demonstrated that SpHb measurement in pediatric craniofacial surgery for craniosynostosis is a safe and non-invasive method to monitor hemoglobin values and help transfusion decision-making, subject to bias and inaccuracies of the device. Researchers concluded that pediatric patients who were monitored with SpHb had lower intraoperative packed red blood cell transfusion, less post-operative bleeding and shorter ICU stays.
Industry Prospects
Per a report by MarketsandMarkets, the global PBM market is projected to reach $15.3 billion by 2024 from $10.7 billion in 2019 at a CAGR of 7.4%. Factors like the rising prevalence of blood disorders, the growing number of blood donations increasing the risk of transfusion-transmitted infections, and escalation in road accidents, injuries, surgeries and trauma are expected to drive the market.
Given the market potential, the positive study outcome is likely to provide a significant boost to Masimo’s business globally.
Notable Developments
This month, Masimo announced a major expansion of its leading hospital remote patient-monitoring and clinician notification platform — Masimo Patient SafetyNet. The expansion includes the addition of secure telehealth capabilities, thereby making the solution more adaptable and comprehensive.
Last month, Masimo received the FDA’s clearance for SedLine brain function monitoring for pediatric patients (one to 17 years of age) and the SedLine Pediatric EEG (electroencephalogram) Sensor. The latest clearance expands access to SedLine for all patients above the age of one in the United States.
Also, in February, Masimo announced robust fourth-quarter 2021 results, wherein it registered a solid uptick in the top line. The company also recorded a strong rebound in sensor sales (on the back of solid demand for set sensors) and robust order shipments.
Price Performance
Shares of Masimo have lost 32% in the past year compared with the industry’s 1.4% fall. The S&P 500 has risen 14.9% in the same time frame.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
Currently, Masimo carries a Zacks Rank #3 (Hold).
A few stocks from the broader medical space that investors can consider are AMN Healthcare Services, Inc. (AMN - Free Report) , Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) and Henry Schein, Inc. (HSIC - Free Report) .
AMN Healthcare has an estimated long-term growth rate of 16.2%. AMN’s earnings surpassed estimates in the trailing four quarters, the average surprise being 20%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
AMN Healthcare has gained 38.5% against the industry’s 53.5% fall over the past year.
Allscripts, carrying a Zacks Rank #2 (Buy), has an estimated long-term growth rate of 16.3%. MDRX’s earnings surpassed estimates in the trailing four quarters, the average surprise being 64.8%.
Allscripts has gained 44.2% against the industry’s 47.3% fall over the past year.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently flaunts a Zacks Rank #1.
Henry Schein has gained 25.9% compared with the industry’s 7.6% rise over the past year.